191 related articles for article (PubMed ID: 17638905)
1. Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone.
Bentle MS; Reinicke KE; Dong Y; Bey EA; Boothman DA
Cancer Res; 2007 Jul; 67(14):6936-45. PubMed ID: 17638905
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.
Dong Y; Bey EA; Li LS; Kabbani W; Yan J; Xie XJ; Hsieh JT; Gao J; Boothman DA
Cancer Res; 2010 Oct; 70(20):8088-96. PubMed ID: 20940411
[TBL] [Abstract][Full Text] [Related]
3. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.
Chakrabarti G; Silvers MA; Ilcheva M; Liu Y; Moore ZR; Luo X; Gao J; Anderson G; Liu L; Sarode V; Gerber DE; Burma S; DeBerardinis RJ; Gerson SL; Boothman DA
Sci Rep; 2015 Nov; 5():17066. PubMed ID: 26602448
[TBL] [Abstract][Full Text] [Related]
4. X-ray repair cross-complementing protein 1 (XRCC1) loss promotes β-lapachone -induced apoptosis in pancreatic cancer cells.
Zheng Y; Zhang H; Guo Y; Chen Y; Chen H; Liu Y
BMC Cancer; 2021 Nov; 21(1):1234. PubMed ID: 34789190
[TBL] [Abstract][Full Text] [Related]
5. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA
Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367
[TBL] [Abstract][Full Text] [Related]
6. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
[TBL] [Abstract][Full Text] [Related]
7. Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair.
Bentle MS; Reinicke KE; Bey EA; Spitz DR; Boothman DA
J Biol Chem; 2006 Nov; 281(44):33684-96. PubMed ID: 16920718
[TBL] [Abstract][Full Text] [Related]
8. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
9. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.
Moore Z; Chakrabarti G; Luo X; Ali A; Hu Z; Fattah FJ; Vemireddy R; DeBerardinis RJ; Brekken RA; Boothman DA
Cell Death Dis; 2015 Jan; 6(1):e1599. PubMed ID: 25590809
[TBL] [Abstract][Full Text] [Related]
10. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
[TBL] [Abstract][Full Text] [Related]
11. Ataxia telangiectasia mutated (ATM) is dispensable for endonuclease I-SceI-induced homologous recombination in mouse embryonic stem cells.
Rass E; Chandramouly G; Zha S; Alt FW; Xie A
J Biol Chem; 2013 Mar; 288(10):7086-95. PubMed ID: 23355489
[TBL] [Abstract][Full Text] [Related]
12. β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells.
Park EJ; Min KJ; Lee TJ; Yoo YH; Kim YS; Kwon TK
Cell Death Dis; 2014 May; 5(5):e1230. PubMed ID: 24832602
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
Bryant HE; Helleday T
Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
[TBL] [Abstract][Full Text] [Related]
14. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
[TBL] [Abstract][Full Text] [Related]
15. Differential requirement for H2AX and 53BP1 in organismal development and genome maintenance in the absence of poly(ADP)ribosyl polymerase 1.
Orsburn B; Escudero B; Prakash M; Gesheva S; Liu G; Huso DL; Franco S
Mol Cell Biol; 2010 May; 30(10):2341-52. PubMed ID: 20231360
[TBL] [Abstract][Full Text] [Related]
16. DNA-PKcs and ATM co-regulate DNA double-strand break repair.
Shrivastav M; Miller CA; De Haro LP; Durant ST; Chen BP; Chen DJ; Nickoloff JA
DNA Repair (Amst); 2009 Aug; 8(8):920-9. PubMed ID: 19535303
[TBL] [Abstract][Full Text] [Related]
17. DNA end resection is needed for the repair of complex lesions in G1-phase human cells.
Averbeck NB; Ringel O; Herrlitz M; Jakob B; Durante M; Taucher-Scholz G
Cell Cycle; 2014; 13(16):2509-16. PubMed ID: 25486192
[TBL] [Abstract][Full Text] [Related]
18. Peroxiredoxin 1 knockdown potentiates β-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals.
He T; Banach-Latapy A; Vernis L; Dardalhon M; Chanet R; Huang ME
Carcinogenesis; 2013 Apr; 34(4):760-9. PubMed ID: 23239746
[TBL] [Abstract][Full Text] [Related]
19. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.
Motea EA; Huang X; Singh N; Kilgore JA; Williams NS; Xie XJ; Gerber DE; Beg MS; Bey EA; Boothman DA
Clin Cancer Res; 2019 Apr; 25(8):2601-2609. PubMed ID: 30617135
[TBL] [Abstract][Full Text] [Related]
20. PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage.
Su X; Wang J; Jiang L; Chen Y; Lu T; Mendonca MS; Huang X
Cancer Lett; 2021 Oct; 519():304-314. PubMed ID: 34329742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
